Products Liability Law Daily Wrap Up, CPSC NEWS—DRUGS—636K bottles of Losartan Potassium and Ezetimibe tablets recalled for failure to meet child-resistant closure requirements, (Sep 3, 2019)

By Colleen Kave, J.D.

The tablets present a poisoning risk if swallowed by children.

Sandoz Inc., of Princeton, New Jersey, has recalled around 636,000 Losartan Potassium and Ezetimibe prescription drug bottles because the prescription drug packaging is not child resistant as required by the Poison Prevention Packaging Act, posing a poisoning risk if swallowed by children (CPSC Recall Notice, No. 19-194, August 29, 2019).

Incidents and injuries. No incidents or injuries have been reported.

Product description. This recall involves bottles of the prescription medications Losartan Potassium and Ezetimibe from Sandoz. The recalled bottles have labels with "Sandoz," the name of the medication, the dosage, and the NDC number on the front, and the lot number and expiration date on the side. A complete list of affected drugs, NDC numbers, lot numbers, and expiration dates is available at www.cpsc.gov.

These prescription drug bottles, which were manufactured in Slovenia, were sold at clinics and pharmacies nationwide as a prescribed medicine from July 2018 through August 2019. The container was included in the price of the medication, which varied based on quantities prescribed, health insurance terms, and other factors.

Remedy. Consumers should secure the medications immediately to keep them out of the sight and reach of children, and contact Sandoz for a free replacement child resistant bottle cap. Once the medication is secured, consumers can continue to use the medication as directed.

Customer contact. For more information, customers may contact Sandoz at 800-525-8747 from 8:30 a.m. to 5 p.m. ET, Monday to Friday, or online at www.us.sandoz.com and click on "Patients and Customers," then "Product Safety Notices."

Companies: Sandoz Inc.

ProductRecalls: ProductRecallsNews DrugsNews